GlassScriptPhysician profile
Joshua Smith
NPI 1104122746
$2,150.88
in general payments reported to CMS, 2019-2025
27 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $767 · 2022: $412 · 2023: $442 · 2024: $240 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $971.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $656.26 | 2021-2025 | |
| Novo Nordisk INC | $498.66 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $118.18 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.69 | 2021-2023 | Trulance, Xifaxan |
| Exact Sciences Corporation | $70.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $69.10 | 2021-2024 | |
| Glaxosmithkline, LLC. | $60.01 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Esperion Therapeutics, INC. | $54.82 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $52.19 | 2021 | |
| Amarin Pharma, INC. | $50.50 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $38.40 | 2021 | |
| Mylan Specialty L.P. | $35.00 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.87 | 2022 | |
| Amgen INC. | $32.66 | 2023-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.23 | 2025 | Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $29.30 | 2025 | Korlym |
| Mayne Pharma Commercial LLC | $29.07 | 2025 | |
| Bausch Health US, LLC | $24.51 | 2022 | |
| Sanofi-Aventis U.S. LLC | $24.29 | 2021 | |
| Inogen, INC. | $23.50 | 2024 | |
| Abbott Laboratories | $23.48 | 2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $22.80 | 2024 | Veozah |
| Genentech USA, INC. | $21.97 | 2021 | |
| Azurity Pharmaceuticals, INC. | $19.94 | 2025 | Azmiro |
| Antares Pharma, INC. | $19.38 | 2025 | Xyosted |
| Astrazeneca Pharmaceuticals LP | $15.92 | 2023 | Bevespi Aerosphere |
| Supernus Pharmaceuticals, INC. | $13.85 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.